SHREE GANESH REMEDIES Latest Share Price (SGRL)
TODAY IN ONE LINE
SGRL slipped 0.9%, lagging Nifty's 2.0% move, supported by recent strong earnings.
With a market cap of ₹813.65 Cr., it trades at a P/E of 50.76. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SHREE GANESH REMEDIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 62.2% and Profit up 45.5%
- ●High Promoter HoldingPromoters hold 72.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest SHREE GANESH REMEDIES News
What changed recently?
Recent events, corporate actions, and announcements.
SHREE GANESH REMEDIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SHREE GANESH REMEDIES, framed against the sector median so the premium or discount is obvious at a glance.
SHREE GANESH REMEDIES trades at a P/E of 50.76× and P/B of 4.81×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SHREE GANESH REMEDIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SHREE GANESH REMEDIES — derived from the latest tape, not yesterday's close.
SHREE GANESH REMEDIES last traded at ₹625.85 with an intraday range of ₹621.75–₹647 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹625.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 691.82 | +65.97 | +10.54% |
| R3 | 666.57 | +40.72 | +6.51% |
| R2 | 656.78 | +30.93 | +4.94% |
| R1 | 641.32 | +15.47 | +2.47% |
| PIVOT | 631.53 | 5.68 | 0.91% |
| CURRENT | 625.85 | — | — |
| S1 | 616.07 | -9.78 | -1.56% |
| S2 | 606.28 | -19.57 | -3.13% |
| S3 | 590.82 | -35.03 | -5.60% |
| S4 | 565.57 | -60.28 | -9.63% |
SGRL is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹630.05–₹647
Trading Inside opening range
SHREE GANESH REMEDIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SHREE GANESH REMEDIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
SHREE GANESH REMEDIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹813.65 Cr. and reported EPS of ₹1.27.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 109 | 109 ▲ 0.0% |
| Sales Growth YoY %Derived | 0.63% | 0.63% |
| Other Income | 3 | 3 ▲ 0.0% |
| Total Income | 112 | 112 ▲ 0.0% |
| 42 | 42 ▲ 0.0% | |
| Gross ProfitDerived | 67 | 67 ▲ 0.0% |
| Gross Margin %Derived | 61.68% | 61.68% |
| 32 | 32 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 35 | 35 ▲ 0.0% |
| OPM %Derived | 32.04% | 32.04% |
| 14 | 14 ▲ 0.0% | |
| Profit Before Tax (PBT) | 24 | 24 ▲ 0.0% |
| 6 | 6 ▲ 0.0% | |
| Effective Tax %Derived | 26.05% | 26.05% |
| Total Profit for Period | 18 | 18 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 18 | 18 ▲ 0.0% |
| Net Profit Margin %Derived | 16.25% | 16.25% |
| PAT Growth YoY %Derived | -23.01% | -23.01% |
| Earnings Per Share (EPS ₹) | 13.83 | 13.83 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 88 | 88 ▲ 0.0% |
| Material Cost % of RevenueDerived | 37.44% | 37.44% |
| Employee Cost % of RevenueDerived | 10.43% | 10.43% |
| Other Cost % of RevenueDerived | 19.21% | 19.21% |
| Interest Coverage (x)Derived | 6.89x | 6.89x |
| Period | Mar 2020 | Aug 2020 | Mar 2024 | Jul 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 64 | 64 ▲ 0.0% | 126 ▲ 96.7% | 126 ▲ 0.0% | 109 ▼ 13.7% | 109 ▲ 0.0% | 109 ▲ 0.6% | 109 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | — | — | -13.74% | — | 0.63% | 0.63% | |
| Other Income | 4 | 4 ▲ 0.0% | 3 ▼ 21.5% | 3 ▲ 0.0% | 4 ▲ 21.6% | 4 ▲ 0.0% | 3 ▼ 18.8% | 3 ▲ 0.0% | |
| Total Income | 68 | 68 ▲ 0.0% | 129 ▲ 89.9% | 129 ▲ 0.0% | 112 ▼ 12.9% | 112 ▲ 0.0% | 112 ▼ 0.0% | 112 ▲ 0.0% | |
38 | 38 ▲ 0.0% | 57 ▲ 51.5% | 57 ▲ 0.0% | 36 ▼ 37.6% | 36 ▲ 0.0% | 42 ▲ 16.7% | 42 ▲ 0.0% | ||
| Gross ProfitDerived | 26 | 26 ▲ 0.0% | 68 ▲ 162.3% | 68 ▲ 0.0% | 73 ▲ 6.2% | 73 ▲ 0.0% | 67 ▼ 7.3% | 67 ▲ 0.0% | |
| Gross Margin %Derived | 40.77% | 40.77% | 54.37% | 54.37% | 66.97% | 66.97% | 61.68% | 61.68% | |
14 | 14 ▲ 0.0% | 27 ▲ 96.1% | 27 ▲ 0.0% | 34 ▲ 25.8% | 34 ▲ 0.0% | 32 ▼ 3.3% | 32 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 13 | 13 ▲ 0.0% | 42 ▲ 234.0% | 42 ▲ 0.0% | 39 ▼ 6.2% | 39 ▲ 0.0% | 35 ▼ 10.7% | 35 ▲ 0.0% | |
| OPM %Derived | 19.55% | 19.55% | 33.21% | 33.21% | 36.11% | 36.11% | 32.04% | 32.04% | |
3 | 3 ▲ 0.0% | 7 ▲ 136.8% | 7 ▲ 0.0% | 12 ▲ 73.8% | 12 ▲ 0.0% | 14 ▲ 20.2% | 14 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 14 | 14 ▲ 0.0% | 38 ▲ 180.8% | 38 ▲ 0.0% | 31 ▼ 18.1% | 31 ▲ 0.0% | 24 ▼ 23.2% | 24 ▲ 0.0% | |
3 | 3 ▲ 0.0% | 10 ▲ 222.2% | 10 ▲ 0.0% | 8 ▼ 18.4% | 8 ▲ 0.0% | 6 ▼ 23.7% | 6 ▲ 0.0% | ||
| Effective Tax %Derived | 22.95% | 22.95% | 26.34% | 26.34% | 26.22% | 26.22% | 26.05% | 26.05% | |
| Total Profit for Period | 10 | 10 ▲ 0.0% | 28 ▲ 168.4% | 28 ▲ 0.0% | 23 ▼ 17.9% | 23 ▲ 0.0% | 18 ▼ 23.0% | 18 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 10 | 10 ▲ 0.0% | 28 ▲ 168.4% | 28 ▲ 0.0% | 23 ▼ 17.9% | 23 ▲ 0.0% | 18 ▼ 23.0% | 18 ▲ 0.0% | |
| Net Profit Margin %Derived | 16.36% | 16.36% | 22.33% | 22.33% | 21.24% | 21.24% | 16.25% | 16.25% | |
| PAT Growth YoY %Derived | — | — | — | — | -17.93% | — | -23.01% | -23.01% | |
| Earnings Per Share (EPS ₹) | 8.15 | 8.15 ▲ 0.0% | 21.88 ▲ 168.5% | 21.88 ▲ 0.0% | 17.97 ▼ 17.9% | 17.97 ▲ 0.0% | 13.83 ▼ 23.0% | 13.83 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▼ 0.0% | 1 ▲ 0.0% | 1 ▼ 0.1% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | — | — | 0 | 0 ▲ 0.0% | -0 ▼ 122.8% | -0 ▲ 0.0% | 0 ▲ 560.9% | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 54 | 54 ▲ 0.0% | 91 ▲ 67.1% | 91 ▲ 0.0% | 81 ▼ 10.7% | 81 ▲ 0.0% | 88 ▲ 8.9% | 88 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 59.84% | 59.84% | 48.49% | 48.49% | 34.42% | 34.42% | 37.44% | 37.44% | |
| Employee Cost % of RevenueDerived | 6.23% | 6.23% | 6.68% | 6.68% | 9.32% | 9.32% | 10.43% | 10.43% | |
| Other Cost % of RevenueDerived | 14.99% | 14.99% | 14.48% | 14.48% | 21.54% | 21.54% | 19.21% | 19.21% | |
| Interest Coverage (x)Derived | 18.84x | 18.84x | 58.80x | 58.80x | 14.07x | 14.07x | 6.89x | 6.89x |
SHREE GANESH REMEDIES segment analysis : revenue and profit mix.
Disclosed business segments at SHREE GANESH REMEDIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
SHREE GANESH REMEDIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SHREE GANESH REMEDIES.
Our AI distills the core fundamental drivers supporting SHREE GANESH REMEDIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 66 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
SHREE GANESH REMEDIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SHREE GANESH REMEDIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SHREE GANESH REMEDIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SHREE GANESH REMEDIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SHREE GANESH REMEDIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SHREE GANESH REMEDIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SHREE GANESH REMEDIES stood at 68.3% of traded volume, against a 20-day average of 58.7%.
SHREE GANESH REMEDIES announcements: results, concalls, ratings, M&A.
Filings SHREE GANESH REMEDIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SHREE GANESH REMEDIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 34 documents below.
Insider Trading / SAST
Intimation of Trading Window Closure
Company Update
Newspaper Publication for Notice of Annual General Meeting
Investor decks & rating reports.
SHREE GANESH REMEDIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SHREE GANESH REMEDIES has declared, sequenced by announce and record date.
SHREE GANESH REMEDIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SHREE GANESH REMEDIES: business, sector, key facts.
What SHREE GANESH REMEDIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SHREE GANESH REMEDIES is a listed Indian equity.
SHREE GANESH REMEDIES
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA HEALTHCARE (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SHREE GANESH REMEDIES (SGRL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SHREE GANESH REMEDIES (SGRL)?
The current share price of SHREE GANESH REMEDIES (SGRL) is ₹625.85. Today, the stock has declined by ₹5.75 (0.91%), trading in a range of ₹621.75 to ₹647.00. The stock opened at ₹647.00 with a trading volume of 8,094 shares.
02Is SHREE GANESH REMEDIES stock a good investment for long-term?
SHREE GANESH REMEDIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹813.65 Cr., P/E ratio of 50.76, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SHREE GANESH REMEDIES stock?
The 52-week high price of SHREE GANESH REMEDIES (SGRL) is ₹749.85, while the 52-week low is ₹477.05. Currently trading at ₹625.85, the stock is 31.19% above its 52-week low and 16.54% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SHREE GANESH REMEDIES stock at the current price?
Whether to buy SHREE GANESH REMEDIES stock at ₹625.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.76 and P/B ratio of 4.81. Today's performance shows a loss of 0.91%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SHREE GANESH REMEDIES and when is the next dividend?
SHREE GANESH REMEDIES offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹625.85, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is SHREE GANESH REMEDIES stock performing today in the market?
SHREE GANESH REMEDIES stock opened at ₹647.00 and is currently trading at ₹625.85, showing a decline of ₹5.75 (0.91%). The intraday high is ₹647.00 and low is ₹621.75. The trading volume stands at 8,094 shares, indicating moderate market participation today.
07What is the P/E ratio of SHREE GANESH REMEDIES and what does it indicate?
SHREE GANESH REMEDIES has a Price-to-Earnings (P/E) ratio of 50.76, which means investors are willing to pay 50.76 for every ₹1 of earnings. With an EPS of ₹1.27, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of SHREE GANESH REMEDIES?
SHREE GANESH REMEDIES has a market capitalization of ₹813.65 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹625.85) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about SHREE GANESH REMEDIES (SGRL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.